financetom
Business
financetom
/
Business
/
DGCA launches investigation into series of safety lapses at SpiceJet after technician death, runway overruns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DGCA launches investigation into series of safety lapses at SpiceJet after technician death, runway overruns
Jul 14, 2019 4:21 AM

India's aviation regulator has initiated an investigation into a series of safety lapses at low-cost airline SpiceJet, which has resulted in the death of a technician and caused planes to veer off runways, people intimately aware of the matter said.

The Directorate General of Civil Aviation (DGCA) has also issued show cause notice to some officials of the company, they said, asking not to be named because of the sensitivity of the issue.

The regulator is also probing the reason behind the death of a SpiceJet technician at Kolkata airport on Wednesday, they said. A SpiceJet technician was killed after the landing gear door of the aircraft he was working on getting "accidentally" shut at the Kolkata airport on Wednesday.

There are unconfirmed reports that SpiceJet has compensated the family of the technician.

The article will be updated with SpiceJet comment.

"A probe is on. Action will be taken based on the findings of the enquiry," one person familiar with the matter told CNBC-TV18.

DGCA has issued notices to the chief of flight safety, operations and training at SpiceJet, which has bounced back from a serious cash crunch in 2015 that nearly shut operations to consistent profits. The chief of flight safety has resigned while executives heading operations and training have been removed and replacements have been put in place, the persons quoted above said.

With the onset of monsoon, there has been an unusual increase in the number of incidents of runway overruns by domestic airlines at Indian airports. At least three have involved a SpiceJet plane at the airports Mumbai and Kolkata.

First Published:Jul 14, 2019 1:21 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Osisko To Purchase Royalties On Spartan Resources' Dalgaranga Gold Project
BRIEF-Osisko To Purchase Royalties On Spartan Resources' Dalgaranga Gold Project
Oct 2, 2024
Sept 30 (Reuters) - Osisko Gold Royalties Ltd ( OR ): * OSISKO ANNOUNCES AGREEMENT TO PURCHASE ROYALTIES ON SPARTAN RESOURCES' DALGARANGA GOLD PROJECT IN WESTERN AUSTRALIA * OSISKO GOLD ROYALTIES LTD ( OR ) - TO ACQUIRE 1.8% GROSS REVENUE ROYALTY ON DALGARANGA GOLD PROJECT * OSISKO GOLD ROYALTIES LTD ( OR ) - TO ACQUIRE 1.35% GROSS REVENUE...
TD Comments on Canada's Economy
TD Comments on Canada's Economy
Oct 2, 2024
07:57 AM EDT, 09/30/2024 (MT Newswires) -- It's been clear for some time that the Canadian economy is operating with slack, said TD. The Bank of Canada certainly reinforced as much in its summer Monetary Policy Report, but perhaps the clearest signal is that Canada's unemployment rate has jumped 1.6 percentage points from its 2023 low, noted the bank. Last...
AT&T Gets Major Exit Cue As DirecTV Clinches Dish Deal
AT&T Gets Major Exit Cue As DirecTV Clinches Dish Deal
Oct 2, 2024
DirecTV has finalized a deal to merge with Dish Network, marking a significant shift in the pay-TV landscape. This would allow AT&T Inc. ( T ) to walk out of DirecTV. What Happened: The merger concludes decades of intermittent discussions, creating a combined entity with 20 million subscribers. This move comes as both companies face declining market shares due to...
Adicet Bio Begins Phase 1 Trial Enrollment for Potential Autoimmune Diseases Therapy
Adicet Bio Begins Phase 1 Trial Enrollment for Potential Autoimmune Diseases Therapy
Oct 2, 2024
07:55 AM EDT, 09/30/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Monday it has opened enrollment for its phase 1 trial evaluating ADI-001, an investigational allogeneic gamma delta CAR T cell therapy, in autoimmune diseases. The company said it is enrolling patients with lupus nephritis and plans to accept patients with systemic lupus erythematosus, systemic sclerosis, and anti-neutrophil...
Copyright 2023-2026 - www.financetom.com All Rights Reserved